middle.news
Alterity Unveils Promising Phase 2 Data for ATH434 at International MSA Congress
3:04am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Alterity Unveils Promising Phase 2 Data for ATH434 at International MSA Congress
3:04am on Monday 2nd of June, 2025 AEST
Key Points
Positive Phase 2 data for ATH434 showing slowed progression in Multiple System Atrophy
Presentations include oral and poster sessions at the 2025 International MSA Congress
ATH434 granted Fast Track and Orphan Drug Designations by US FDA and European Commission
Ongoing bioMUSE natural history study collaboration with Vanderbilt University Medical Center
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE